CORCEPT THERAPEUTICS INC Cash and Cash Equivalents, Fair Value Disclosure
CORCEPT THERAPEUTICS INC (CORT) had Cash and Cash Equivalents, Fair Value Disclosure of $54.88 million as of 2013-12-31, per its 10-K filed 2014-03-14.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2014-03-14
- 2013-12-31: Cash and Cash Equivalents, Fair Value Disclosure $54.88M.
- 2012-12-31: Cash and Cash Equivalents, Fair Value Disclosure $93.03M.
- 2012-06-30: Cash and Cash Equivalents, Fair Value Disclosure $34.90M.
- 2011-12-31: Cash and Cash Equivalents, Fair Value Disclosure $39.63M; Cash and Cash Equivalents, Fair Value Disclosure as first filed $39.60M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure | Cash and Cash Equivalents, Fair Value Disclosure as first filed |
|---|---|---|
| 2013-12-31 | $54.88M 10-K · filed 2014-03-14 | |
| 2012-12-31 | $93.03M 10-K · filed 2014-03-14 | |
| 2012-06-30 | $34.90M 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $39.63M 10-K · filed 2013-03-15 | $39.60M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |